Medication info
Telostop Tablet 40/20 Milligrams

Telostop Tablet 40/20 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/bottle, 30 tablets/box [(10 tablets/Alu-Alu)x3]
Approval status
Active

MFDS item code 201504096 · Approved 2015.06.23 · Insurance code 642905510

Summary

Main use
Treatment of hypertension and dyslipidemia, reduction of cardiovascular risk, and inhibition of the progression of atherosclerosis
Who takes it
Adults
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This drug provides additional blood pressure-lowering effects when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this drug is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this drug to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this drug, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, reduction of cardiovascular risk, and inhibition of the progression of atherosclerosis

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require concomitant treatment with telmisartan and rosuvastatin. Telmisartan primarily helps reduce the risk of myocardial infarction, stroke, and cardiovascular disease death in high-risk cardiovascular patients who cannot use ACE inhibitors. Rosuvastatin Calcium is utilized for treating hypercholesterolemia and dyslipidemia, and is used as an adjunct when dietary measures and exercise are insufficient. It is also effective in delaying the progression of atherosclerosis and reducing cardiovascular disease risk. This combination helps improve overall cardiovascular health in patients with hypertension and hyperlipidemia.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This drug provides additional blood pressure-lowering effects when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this drug is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this drug to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this drug, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with known allergies to this medication, pregnant or potentially pregnant women, and nursing mothers should not take it. Patients with severe liver or kidney dysfunction, or those with specific liver or muscle diseases, should also refrain from using this medication. Caution is needed for the elderly, patients with high potassium levels, and those with mild to moderate liver impairment, and regular checks on liver function and muscle condition are required. If symptoms such as myalgia or muscle weakness occur, contact a doctor immediately and undergo necessary examinations. This medication may interact when taken with other antihypertensives or certain lipid-lowering agents, so inform your doctor about any medications currently being taken. Regular monitoring of liver function tests and blood tests is required during treatment to check for abnormalities. Care should be taken when driving or operating machinery, as drowsiness or dizziness may occur. It is not recommended for children as safety has not been established. In case of an overdose, symptoms such as hypotension, dizziness, and renal dysfunction may occur, necessitating immediate medical assistance. This medication contains lactose, so patients with lactose intolerance should not take it. Consult with your doctor before and after taking the medication, and report any unusual symptoms immediately for appropriate action.

Side effects

Headache, orthostatic dizziness, sleep paralysis, hypertension, hypotension, low blood pressure, elevated ALT, dysuria, rhinitis, discomfort in oropharynx, pulmonary diseases, unspecified gastrointestinal diseases, benign gastrointestinal tumors, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infections, urinary tract infections, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, respiratory distress, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, respiratory distress, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, headache, facial spasm, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, ear noises, petechiae, palpitations, fatigue, nausea, lack of effectiveness, headache, dizziness, cough, dyspepsia, palpitations, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, fainting, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, hypotension, tachycardia, bradycardia, acute renal failure, shock, loss of consciousness, liver dysfunction, jaundice, anaphylaxis-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of effectiveness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, maintaining a storage temperature between 1 degree and 30 degrees Celsius at room temperature. It is important to avoid direct sunlight and not to keep it in excessively hot or cold places.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 30 tablets/box [(10 tablets/Alu-Alu)x3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.